Nurix Therapeutics, Inc. (NRIX)
Market Cap | 401.02M |
Revenue (ttm) | 60.94M |
Net Income (ttm) | -157.44M |
Shares Out | 48.20M |
EPS (ttm) | -2.96 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 335,046 |
Open | 8.53 |
Previous Close | 8.52 |
Day's Range | 8.26 - 8.67 |
52-Week Range | 8.12 - 15.09 |
Beta | 1.61 |
Analysts | Strong Buy |
Price Target | 27.56 (+231.25%) |
Earnings Date | Oct 9, 2023 |
About NRIX
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casita... [Read more]
Financial Performance
In 2022, NRIX's revenue was $38.63 million, an increase of 29.84% compared to the previous year's $29.75 million. Losses were -$180.36 million, 53.9% more than in 2021.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price forecast is $27.56, which is an increase of 231.25% from the latest price.
News

Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati...

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin's lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Recei...

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a rapid and sustained complete response; Phase 1b expansion cohort also initiated...

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 09, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patie...

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations
Oral presentation features structural disclosure and preclinical characterization of NX-2127, Nurix's lead BTK degrader for the treatment of B-cell malignancies

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update
Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment

Nurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat...

Nurix's stock rallies on Gilead's option
Shares of Nurix Therapeutics Inc. NRIX, -0.99% gained about 6% in premarket trading on Monday after Gilead Sciences Inc. GILD, -3.18% said it exercised the option to exclusively license Nurix's target...

Gilead Exercises Option to License Nurix's IRAK4 Targeted Protein Degrader Development Candidate, NX-0479
FOSTER CITY, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted p...

Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting
Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948 Nurix to report additional preclinical data for its targeted BTK degraders NX-2127 and NX-5948

Nurix Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
SAN FRANCISCO, March 06, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat...

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update
Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities
Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform

Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pati...

Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton's tyrosine kinase (BTK) mutational status

Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET) Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)

Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in
Presentations highlight use of Nurix's first-in-class CBL-B inhibitor NX-0255 to enhance growth and profile of T cells for cell therapy in DeTIL-0255 program Presentations highlight use of Nurix's fir...

Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor

Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignancies Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in p...

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin's Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL)

Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that ...

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update
Completed two registered direct offerings in July raising gross proceeds of $95 million

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors
SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the ...

Nurix Therapeutics Announces $40 Million Registered Direct Offering
SAN FRANCISCO, July 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that ...